AU2004312511A1 - Benzo(d)isoxazol-3-ol DAAO inhibitors - Google Patents

Benzo(d)isoxazol-3-ol DAAO inhibitors Download PDF

Info

Publication number
AU2004312511A1
AU2004312511A1 AU2004312511A AU2004312511A AU2004312511A1 AU 2004312511 A1 AU2004312511 A1 AU 2004312511A1 AU 2004312511 A AU2004312511 A AU 2004312511A AU 2004312511 A AU2004312511 A AU 2004312511A AU 2004312511 A1 AU2004312511 A1 AU 2004312511A1
Authority
AU
Australia
Prior art keywords
hydrogen
alkyl
aryl
pharmaceutical composition
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004312511A
Other languages
English (en)
Inventor
Milan Chytil
Q. Kevin Fang
Michele Heffernan
Seth Hopkins
Peter Wipf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma America Inc
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of AU2004312511A1 publication Critical patent/AU2004312511A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AU2004312511A 2003-12-29 2004-12-28 Benzo(d)isoxazol-3-ol DAAO inhibitors Abandoned AU2004312511A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53297803P 2003-12-29 2003-12-29
US60/532,978 2003-12-29
PCT/US2004/043547 WO2005066143A2 (en) 2003-12-29 2004-12-28 Benzo[d]isoxazol-3-ol daao inhibitors

Publications (1)

Publication Number Publication Date
AU2004312511A1 true AU2004312511A1 (en) 2005-07-21

Family

ID=34748836

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004312511A Abandoned AU2004312511A1 (en) 2003-12-29 2004-12-28 Benzo(d)isoxazol-3-ol DAAO inhibitors

Country Status (15)

Country Link
US (1) US7166725B2 (enExample)
EP (1) EP1711478A2 (enExample)
JP (1) JP2007534657A (enExample)
KR (1) KR20060128978A (enExample)
CN (3) CN101798291A (enExample)
AU (1) AU2004312511A1 (enExample)
BR (1) BRPI0417910A (enExample)
CA (1) CA2552098A1 (enExample)
CZ (1) CZ2006426A3 (enExample)
IL (1) IL176607A0 (enExample)
NZ (1) NZ548213A (enExample)
PL (1) PL380766A1 (enExample)
RU (1) RU2384574C2 (enExample)
WO (1) WO2005066143A2 (enExample)
ZA (1) ZA200605384B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004312530A1 (en) 2003-12-29 2005-07-21 Sepracor Inc. Pyrrole and pyrazole DAAO inhibitors
CA2472806A1 (en) 2004-05-18 2005-11-18 Petro-Canada Compositions and methods for treating turf insect pests and diseases such as fungal infestations
JP2009500425A (ja) 2005-07-06 2009-01-08 セプラコア インコーポレーテッド エスゾピクロン及びトランス４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロ−ｎ−メチル−１−ナフタレンアミン又はトランス４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロ−１−ナフタレンアミンの組み合わせ、並びに閉経期並びに気分、不安、及び認知障害の治療方法
BRPI0706365A2 (pt) 2006-01-06 2011-03-22 Sepracor Inc Cicloalquilaminas como inibidores da recaptação de monoamina
NZ569608A (en) * 2006-01-06 2011-09-30 Sepracor Inc Tetralone-based monoamine reuptake inhibitors
EP1988085B8 (en) 2006-02-21 2015-01-28 Toyama Chemical Co., Ltd. Process for production of 3-[5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]-2-[(3-hydroxy-1,2-benzisoxazol-6-yl)methoxy]phenyl]propionate ester and intermediate for the process
DK2816024T3 (en) 2006-03-31 2017-10-30 Sunovion Pharmaceuticals Inc CHIRALE AMINER
US7884124B2 (en) * 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
US7579370B2 (en) * 2006-06-30 2009-08-25 Sepracor Inc. Fused heterocycles
US20080082066A1 (en) * 2006-10-02 2008-04-03 Weyerhaeuser Co. Crosslinked carboxyalkyl cellulose fibers having non-permanent and temporary crosslinks
US9357768B2 (en) 2006-10-05 2016-06-07 Suncor Energy Inc. Herbicidal composition with increased herbicidal efficacy
US20090099248A1 (en) * 2007-01-18 2009-04-16 Sepracor Inc. Inhibitors of d-amino acid oxidase
US7902252B2 (en) * 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
AU2008259841B2 (en) 2007-05-31 2015-02-05 Sunovion Pharmaceuticals Inc. Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
ES2619731T3 (es) 2008-06-26 2017-06-26 Suncor Energy Inc. Formulación fungicida para hierba de césped mejorada con pigmento
WO2010017418A1 (en) * 2008-08-07 2010-02-11 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
EP2389187B1 (en) 2009-01-20 2016-11-16 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical
WO2011017634A2 (en) * 2009-08-07 2011-02-10 Sepracore Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
AU2011301171C1 (en) 2010-09-09 2015-09-10 Nutrien Ag Solutions (Canada) Inc. Synergistic paraffinic oil and boscalid fungicides
AU2012381990B2 (en) 2012-06-04 2017-02-23 Nutrien Ag Solutions (Canada) Inc. Formulations containing paraffinic oil and anti-settling agent
WO2014025993A1 (en) 2012-08-08 2014-02-13 The Johns Hopkins University Inhibitors of d-amino acid oxidase
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
CN103435561B (zh) * 2013-08-19 2016-08-10 上海交通大学 一种新型d-氨基酸氧化酶抑制剂及其制备和应用
WO2015147742A1 (en) * 2014-03-24 2015-10-01 Kaohsiung Chang Gung Memorial Hospital Use of benzoic acid salt in the manufactue of a composition for preventing or treating dementia or mild cognitive impairment
CN105801511B (zh) * 2016-04-22 2018-01-02 山西大学 一种1,2‑苯并异恶唑啉‑3‑酮的制备方法
US11008277B2 (en) 2016-06-13 2021-05-18 Syneurx International (Taiwan) Corp. Co-crystals of sodium benzoate and uses thereof
US10815184B2 (en) 2016-06-13 2020-10-27 Syneurx International (Taiwan) Corp. Co-crystals of lithium benzoate and uses thereof
CA2938096C (en) 2016-08-04 2019-02-26 Suncor Energy Inc. Stabilized emulsions
US11369579B2 (en) 2016-10-24 2022-06-28 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
US10336679B2 (en) 2016-10-24 2019-07-02 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
JP6550426B2 (ja) * 2017-07-26 2019-07-24 カオシュン・チャン・グン・メモリアル・ホスピタル 認知症または軽度認知障害を予防または治療する組成物を製造するための安息香酸塩の使用
WO2019043635A1 (en) 2017-09-01 2019-03-07 Richter Gedeon Nyrt. COMPOUNDS INHIBITING THE ACTIVITY OF D-AMINO ACID OXIDASE
US10336724B2 (en) * 2017-10-18 2019-07-02 Syneurx International (Taiwan) Corp. D-amino acid oxidase inhibitors and therapeutic uses thereof
US10098861B1 (en) 2017-10-24 2018-10-16 Syneurx International (Taiwan) Corp. Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof
WO2020150831A1 (en) 2019-01-25 2020-07-30 Suncor Energy Inc. Photosensitizer compounds, methods of manufacture and application to plants
CN113677204B (zh) 2019-02-15 2024-03-05 桑科能源股份有限公司 原卟啉ix衍生物改善植物健康的用途
CN117362246B (zh) * 2023-12-04 2024-03-12 烟台海川化学制品有限公司 一种3-苯基-1,4,2-二恶唑-5-酮的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58177915A (ja) * 1982-04-12 1983-10-18 Green Cross Corp:The 抗血栓剤
US4738709A (en) * 1985-01-10 1988-04-19 Ppg Industries, Inc. Herbicidally active substituted benzisoxazoles
JPH0477476A (ja) * 1990-07-19 1992-03-11 Sankyo Co Ltd 抗潰瘍剤
CA2146755A1 (en) * 1992-10-28 1994-05-11 Kenji Takeda Novel 1,2-benzoisoxazole derivative or its salt and brain-protecting agent comprising the same
ES2208690T3 (es) * 1994-08-30 2004-06-16 Sankyo Company Limited Isoxazol.
US5484763A (en) * 1995-02-10 1996-01-16 American Cyanamid Company Substituted benzisoxazole and benzisothiazole herbicidal agents
US5620997A (en) * 1995-05-31 1997-04-15 Warner-Lambert Company Isothiazolones
DE19960917A1 (de) * 1999-12-17 2001-06-21 Bayer Ag Neue 3-Oxo-2,1-benzisoxazol-1(3H)-carboxamide zur Behandlung von ZNS-Erkrankungen
JP2001247462A (ja) * 2000-03-07 2001-09-11 Otsuka Pharmaceut Co Ltd ウレアーゼ阻害剤
CA2559105A1 (en) 2004-03-16 2005-09-29 Janssen Pharmaceutica N.V. Benzisoxazoles

Also Published As

Publication number Publication date
KR20060128978A (ko) 2006-12-14
US20050143434A1 (en) 2005-06-30
RU2384574C2 (ru) 2010-03-20
US7166725B2 (en) 2007-01-23
JP2007534657A (ja) 2007-11-29
CN102010382A (zh) 2011-04-13
WO2005066143A3 (en) 2005-10-20
CN1922157A (zh) 2007-02-28
IL176607A0 (en) 2006-10-31
NZ548213A (en) 2010-05-28
ZA200605384B (en) 2007-10-31
BRPI0417910A (pt) 2007-04-10
CZ2006426A3 (cs) 2006-10-11
CN101798291A (zh) 2010-08-11
PL380766A1 (pl) 2007-03-19
EP1711478A2 (en) 2006-10-18
RU2006127436A (ru) 2008-02-10
CA2552098A1 (en) 2005-07-21
CN1922157B (zh) 2011-01-12
WO2005066143A2 (en) 2005-07-21

Similar Documents

Publication Publication Date Title
US7166725B2 (en) Benzo[d]isoxazol-3-ol DAAO inhibitors
US7615572B2 (en) Pyrrole and pyrazole DAAO inhibitors
US7579370B2 (en) Fused heterocycles
US10273214B2 (en) Subunit selective NMDA receptor potentiators for the treatment of neurological conditions
US20030162825A1 (en) D-amino acid oxidase inhibitors for learning and memory
JP2022065035A (ja) α５含有ＧＡＢＡＡ受容体アゴニストによる神経変性および神経精神障害における認知症状および気分症状の処置
MXPA06007536A (en) Benzo[d]isoxazol-3-ol daao inhibitors
MXPA06007537A (es) Inhibidores de pirrol y pirazol de d-aminoacido-oxidasa (daao)
KR100267707B1 (ko) Nmda 수용체 길항제로 작용하는 4-치환-퀴놀린-2-카복실산 유도체

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE CO-INVENTOR TO READ HEFFERNAN, MICHELE AND FANG, Q. KEVIN AND WIPF, PETER AND CHYTIL, MILAN AND HOPKINS, SETH

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application